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strongest predictive factors and to derive optimum cut-off 
values for predicting likelihood of toxicity incidence. 
 
Results: Grade ≥2 acute RTOG upper GI toxicity attributed to 
treatment was seen in 11 patients (52%), grade ≥3 in 3 (14%); 
grade ≥2 diarrhoea was recorded in 3 patients (14%), grade ≥3 
in 2 (10%). In patients who experienced grade ≥2 toxicity, 
stomach V15-55 Gy (absolute volume of stomach receiving 
15-55 Gy, in cm3) were significantly larger when compared to 
those without (p<0.05, Mann-Whitney). Differences in V35 Gy 
and V40 Gy remained significant after Bonferroni correction 
(p<0.004) and ROC analysis was performed to identify the 
most predictive cut-off values: V35 Gy 55.7cm3 and V40 Gy 
43.6 cm3 (both sensitivity 0.82, specificity 0.80, Youden 
index = 0.62). Significant associations were not seen between 
duodenal dose-volume and acute toxicity, nor between small-
bowel dose-volume and incidence of treatment-related 
diarrhoea.  
 
 
 
Conclusion: In concomitant chemoradiotherapy with 
nelfinavir for pancreatic cancer, stomach dosimetric 
parameters were associated with clinically important acute 
radiotherapy toxicity and thresholds were derived for 
predicting toxicity risk. Stomach V35 Gy and V40 Gy were 
most strongly predictive of acute grade ≥2 side effects. 
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Purpose or Objective: Tolerance of small bowel is the dose 
limiting factor in radiation therapy for abdominal neoplasms. 
Bowel constraints for treatment planning in abdominal 
radiotherapy derive from scientific publications of pelvic 
tumors. This study has the aim to evaluate dose tolerance of 
small bowel detecting acute toxicities in patients with 
pancreatic cancer treated with radiochemotherapy. 
 
Material and Methods: Patients with pancreatic cancer were 
treated between 2009 and 2014 with 3D-conformal 
radiotherapy with a total dose of 5040 cGy and conventional 
fractionation. Chemotherapy with gemcitabine or 
fluoropyrimidine was simultaneously administered. Nausea, 
vomit and loss of weight, as acute upper gastrointestinal (GI) 
toxicities, were scheduled using RTOG scale. In all patients 
small bowel loops and bowel sac were contoured using 
QUANTEC guidelines and DVHs were analyzed for this 
structures using R statistical software (http://www.R-
project.org). 
 
Results: Forty-three patients with a median age of 66 years 
(range 42-79), 14 resected and 29 unresected, were 
analyzed. Fourteen (32%) patients reported no upper GI 
toxicity; on 8 (19%), 12 (28%) and 9 (21%) patients were 
observed respectively grade 1, 2 and 3 toxicity. No grade 4 
toxicity was recorded. Nineteen patients discontinued 
radiotherapy but all of them completed the treatment. 
Analyzing V Dose on DVHs by logistic regression, small bowel 
loops V36 Gy resulted as the parameter which most 
influenced upper GI G1 or higher Toxicity (p<0.05). 
Multivariate analysis showed no impact of surgery on upper GI 
toxicity. 
 
Conclusion: Our preliminary analysis suggests that new 
constraints for radiochemotherapy in upper GI cancer could 
be upgraded. Our study has to be confirmed on a larger 
sample. 
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Purpose or Objective: Specific results of SBRT for liver 
metastases from rare tumors have been reported scarcely. 
This applies also to metastases from low grade 
neuroendocrine tumors (NET), either derived from 
gastrointestinal organs or from an unknown primary site. 
Here we report two cases of multiple liver metastases from 
low grade NET repeatedly treated by means of SBRT, 
achieving the outcome of long-term local control. 
 
Material and Methods: From March 2011 to September 2015 
49 SBRT courses were delivered to 39 patients for liver 
metastases from different primaries. All courses were given 
by VMAT with 6 MV photons, image guided by CBCT in every 
fraction. Since 2013, deep inspiration breath hold was 
adopted in order to control organ motion. Two patient had 
metastases from well differentiated neuroendocrine tumors, 
one from an unknown primary (patient A), the other from a 
pancreatic primary (patient B). Patient A underwent two 
SBRT courses, both in 2011, the first one on segment 6 (CTV 
volume 25 ml, CTV dose 75 Gy, PTV 50 Gy, in 3 fractions), 
the second one on two adjacent metastases, respectively in 
segment 7 and 8 (total CTV volume 54 ml, CTV dose 60 Gy, 
PTV 50 Gy, in 3 fractions).Patient B received three courses, 
respectively in 2013, 2014 and 2015. The first SBRT was 
delivered on segment 6 (CTV volume 38 ml, CTV dose 50 Gy, 
PTvV45 Gy, in 5 fractions), the second on segment 8 (CTV 
volume 30 ml, CTV dose 50 Gy, PTV 45 Gy, in 5 fractions), 
the last on segment 4 (CTV volume 44 ml, CTV dose 50 Gy, 
PTV 45 Gy, in 5 fractions ). Patient A was found to be 
somatostatine receptor-negative, thus he was followed up 
mainly by serial CT scans; also, his disease status matched 
well to trends of two biomarkers (chromogranin A and 
gastrin). Patient B was followed up by alternating CT scans 
and PET/CT-68Ga-DOTATOC. 
 
Results: At last follow up patient A achieved long-term local 
control in S6 metastasis (45 months) as well as in S7-8 (42 
months), while showing disease progression at a new liver 
site at 45 months after first SBRT. At last follow up patient B 
achieved local control in all sites (S6: 30 months; S8: 13 
months; S4: 6 months) with a durable partial PET response in 
S8 and S4 and a complete PET response in S6. Disease 
progression took place in two bone sites at 30 months after 
first SBRT, without any concomitant liver progression. 
 
